Microbot Medical has secured a three-year exclusive agreement with Medtechnica to distribute its Liberty endovascular robotic system in Israel.
Liberty is a single-use, remotely operated robotic system for peripheral endovascular procedures. The system, which is cleared by the U.S. Food and Drug Administration (FDA), is designed to support vascular navigation while reducing radiation exposure and physical strain for physicians, according to the company.
Microbot received regulatory approval from the Israeli Ministry of Health in May and said it expects initial orders from Medtechnica in the fourth quarter of 2026.
